

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.co

Pinnacle Blooms Network to scale AI-powered child development operating system with \$70 M funding

29 December 2025 | News

Capital deployment would fund expansion from 70+ to 300 centres within 24 months



A leading global healthcare investment fund has offered \$70 million to Pinnacle Blooms Network, the flagship pediatric-therapy enterprise of Hyderabad-based startup Bharath Healthcare Laboratories.

The proposed two-tranche Series A investment, advised by Yukon Capital, would represent one of the largest early-stage financings in child-development infrastructure anywhere in Asia. The offer comes as Pinnacle evaluates strong interest from multiple global institutional investors seeking exposure to the fast-emerging developmental health sector.

Pinnacle operates more than 70 multi-disciplinary therapy centres across India - and has delivered over 20 million one-to-one therapy sessions to date. The company's proprietary Pinnacle Child Development Operating System (GPT-OS®) is a multi-patent-filed digital-therapeutic platform that measures, forecasts, and personalises every dimension of a child's developmental journey across speech, motor, cognitive, and behavioural domains.

The GPT-OS® architecture integrates modules including Diagnosis, Prognosis, TherapeuticAI®, AbilityScore®, Seven Readiness Indexes®, and TherapySphere™—multi-sensory therapeutic environments designed to accelerate neurological development in children with autism, speech delays, ADHD, and related conditions.

The proposed funding is structured in two phases. Phase 1 comprises \$70 million for rapid domestic expansion and technology acceleration. Phase 2 envisions a follow-on tranche as Pinnacle expands into Southeast Asia and the GCC. Capital deployment would fund expansion from 70+ to 300 centres within 24 months, R&D acceleration for home-based TherapeuticAI® applications, large-scale manufacturing of TherapySphere™ sensory rooms, and regulatory submissions for international market access. Pinnacle is targeting expansion with projected annual revenue scaling from Rs 160+ crore to Rs 6,000 crore.

On 23 September 2026, Pinnacle Blooms Network published a source ledger for six company measures on its Verify evidence hub. The ledger defines each measure, its 17 July 2026 cutoff, counting method and location in two accountant reports signed on 3 September 2026. Those reports have different scopes: an SRS 4400 factual-finding engagement and an SAE 3000 limited-assurance engagement. Their limits are stated beside the figures.

One frequently cited figure is 31,052,382 services. In this ledger, “services” includes assessments, screenings and parent training as well as therapy-related services. It is not a count of 31 million one-to-one therapy sessions or unique children, and it does not establish clinical outcomes. The 16 patent entries are applications, not granted patents.

A separate MD-5 source record identifies PinnacleAI GPT-OS version 1.0.0 as Class B, non-diagnostic developmental-support software for children aged 0–12. The record does not grant authority to diagnose autism or prove clinical effectiveness. Verify also separates research preprints, protocols and reports from any later peer-reviewed evidence, with author and version links where available.

The public ledger and MD-5 record let readers inspect specific statements against dated sources. Neither registration nor company scale should be read as an endorsement or a guarantee of benefit for an individual child.

Source ledger: <https://www.pinnacleblooms.org/verify/evidence/claim-ledger.html>

MD-5 record: <https://www.pinnacleblooms.org/verify/evidence/records/md5.html>